Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
APRI is in the long-term down -99% below S&P in 5 years.
Description: Apricus Biosciences, Inc., a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for men?s and women?s health. The company?s lead product, Vitaros, has approved for the treatment of erectile dysfunction in Canada and Europe. It is also developing Vitaros product candidate (room temperature Vitaros) that is a proprietary stabilized dosage formulation, which can be stored at room temperature conditions. The company?s product candidate in the areas of women?s health includes Femprox, an alprostadil-based cream product candidate intended for the treatment of female sexual interest/arousal disorder that has completed an approximately 400-subject proof-of-concept study. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-1.16||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-91.29%||Sales Growth - Q/Q||-75.09%||P/E||-0.93|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-126.99%||ROE||-1493.17%||ROI|
|Current Ratio||2.52||Quick Ratio||2.49||Long Term Debt/Equity||Debt Ratio||4.29|
|Gross Margin||88.18%||Operating Margin||-258.25%||Net Profit Margin||-256.17%||Dividend Payout Ratio|
|Cash From Financing Activities||11.05 M||Cash From Investing Activities||-170 K||Cash From Operating Activities||-6.13 M||Gross Profit||240 K|
|Net Profit||-6.41 M||Operating Profit||-6.12 M||Total Assets||19.64 M||Total Current Assets||18.04 M|
|Total Current Liabilities||7.16 M||Total Debt||4.83 M||Total Liabilities||17.97 M||Total Revenue||470 K|
|High 52 week||3.19||Low 52 week||0.26||Last close||0.28||Last change||-15.15%|
|RSI||52.38||Average true range||0.03||Beta||0.51||Volume||153.23 K|
|Simple moving average 20 days||-3.66%||Simple moving average 50 days||-16.96%||Simple moving average 200 days||-70.3%|
|Performance Week||-9.68%||Performance Month||-1.44%||Performance Quart||9.08%||Performance Half||-67.82%|
|Performance Year||-82.05%||Performance Year-to-date||-84.78%||Volatility daily||4.48%||Volatility weekly||10.02%|
|Volatility monthly||20.54%||Volatility yearly||71.16%||Relative Volume||70.45%||Average Volume||816.79 K|
|New High||New Low|
2019-01-24 08:01:00 | Seelos Therapeutics, Inc. Announces Successful Completion of its Merger with Apricus Biosciences, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System CNS Disorders
2019-01-15 07:00:00 | Apricus Biosciences Stockholders Approve Proposed Merger with Seelos Therapeutics, Inc.
2018-12-14 12:30:00 | Apricus Biosciences Adjourns Special Meeting of Stockholders to New Date
2018-11-16 08:30:00 | Report: Exploring Fundamental Drivers Behind Zedge, Apricus Biosciences, AquaBounty Technologies, Clarus, Dynasil Corporation of America, and The Rubicon Project — New Horizons, Emerging Trends, and Upcoming Developments
2018-10-31 16:30:48 | Apricus: 3Q Earnings Snapshot
2018-10-31 16:24:49 | Apricus Biosciences Provides Corporate Update and Third Quarter 2018 Financial Results
2018-08-09 18:18:39 | Apricus: 2Q Earnings Snapshot
2018-08-09 16:05:00 | Apricus Biosciences Provides Corporate Update and Second Quarter 2018 Financial Results
2018-07-02 07:05:00 | Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks
2018-06-04 14:02:20 | What Does Apricus Biosciences Inc’s NASDAQ:APRI Share Price Indicate?
2018-06-04 07:30:00 | Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks
2018-05-24 17:23:20 | With A -24.18% Earnings Drop, Is Apricus Biosciences Inc’s NASDAQ:APRI A Concern?
2018-05-03 17:40:41 | Apricus: 1Q Earnings Snapshot
2018-05-03 16:02:01 | Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results:
2018-04-16 08:41:56 | Benzinga Pro's 5 Stocks To Watch Today
2018-04-16 08:25:54 | Apricus mulls options; to sell U.S. rights to Vitaros
2018-04-16 07:06:47 | FDA asks for new formulation of Apricus' erectile dysfunction cream
2018-04-16 07:01:00 | Apricus Biosciences Announces Outcome of VitarosTM End-of-Review Meeting with FDA
2018-04-16 07:00:00 | Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA
2018-04-04 16:01:00 | Apricus Biosciences Announces Closing of $3.55 Million Public Offering
2018-03-29 06:31:39 | Edge Therapeutics And Apricus Biosciences Are Moving: Here’s Why
2018-03-28 08:01:01 | Apricus Biosciences Announces Pricing of $3.55 Million Public Offering
2018-03-27 16:40:04 | Apricus Biosciences Announces Proposed Public Offering
2018-03-26 15:26:01 | Apricus Biosciences Announces Scheduling of VitarosTM End-of-Review Meeting with FDA
2018-03-26 07:00:00 | Apricus Biosciences Announces Scheduling of Vitaros™ End-of-Review Meeting with FDA
2018-03-22 08:05:00 | Apricus Biosciences, Vitaros Update, The ED Market, Analysts Target Price, Pipeline
2018-03-06 08:01:22 | Edited Transcript of APRI earnings conference call or presentation 1-Mar-18 9:30pm GMT
2018-03-01 17:09:16 | Apricus reports 4Q loss
2018-03-01 12:00:00 | Apricus Biosciences, Inc. to Host Earnings Call
2018-03-01 11:15:19 | At $0.9401, Is Apricus Biosciences Inc NASDAQ:APRI A Buy?
2018-02-28 10:08:00 | Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates
2018-02-21 08:50:01 | Apricus Biosciences APRI Soars: Stock Adds 8.6% in Session
2018-02-20 10:41:02 | Here’s What’s Moving Apricus Biosciences And Pacira Pharmaceuticals
2018-02-20 09:39:50 | What's Next For Apricus Biosciences' Vitaros?
2018-02-16 12:20:16 | Is It “Game Over” After Apricus Biosciences Inc APRI FDA Rejection?
2018-02-16 11:23:39 | There's No Place Like Home in Biotech
2018-02-16 08:59:11 | Shares of Apricus tank after FDA declines to OK erectile dysfunction cream
2018-02-16 08:52:09 | Benzinga Pro's 5 Stocks To Watch Today
2018-02-16 07:07:47 | U.S. FDA declines to approve Apricus' erectile dysfunction cream
2018-02-16 07:01:01 | Apricus Biosciences Receives Complete Response Letter from FDA for VitarosTM
2018-02-16 07:00:00 | Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™
2017-11-21 13:39:09 | Should You Buy Apricus Biosciences Inc APRI Now?